Association of Conflicts of Interest for Public Speakers for the Peripheral and Central Nervous System Drugs Advisory Committee of the US Food and Drug Administration With Their Statements-Reference-Cited by-同舟云学术

Association of Conflicts of Interest for Public Speakers for the Peripheral and Central Nervous System Drugs Advisory Committee of the US Food and Drug Administration With Their Statements

Published:2019-03-01 Issue:3 Volume:76 Page:368
ISSN:2168-6149
Container-title:JAMA Neurology
language:en
Short-container-title:JAMA Neurol

Author:

Arthur Wade¹,Austin Jennifer¹,Wayant Cole¹,Vassar Matt¹

Affiliation:

1. Oklahoma State University Center for Health Sciences, Tulsa

Publisher

American Medical Association (AMA)

Subject

Clinical Neurology

Link

http:///jamaneurology/article-pdf/76/3/368/17356136/jamaneurology_arthur_2018_ld_180009.pdf

Reference6 articles.

1. Approving a problematic muscular dystrophy drug: implications for FDA policy.;Kesselheim;JAMA,2016

2. Real-world evidence, public participation, and the FDA.;Schwartz;Hastings Cent Rep,2017

3. Conflicts of Interest of Public Speakers at Meetings of the Anesthetic and Analgesic Drug Products Advisory Committee.;McCoy;JAMA Intern Med,2018

4. Characteristics and conflicts of public speakers at meetings of the Oncologic Drugs Advisory Committee to the US Food and Drug Administration.;Abola;JAMA Intern Med,2016

5. Center for Drug Evaluation, Research, Peripheral, and Central Nervous System Drugs Advisory Committee.https://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/PeripheralandCentralNervousSystemDrugsAdvisoryCommittee/default.htm. Accessed August 2, 2018.

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cross-sectional analysis of financial relationships between board certified allergists and the pharmaceutical industry in Japan;BMC Medical Ethics;2024-02-20

2. The Regulatory Repercussions of Approving Muscular Dystrophy Medications on the Basis of Limited Evidence;Annals of Internal Medicine;2023-09

3. Actors in conflict of interest in Iran's health system: Ranking and policy recommendations for conflict of interest management;World Medical & Health Policy;2023-02-07

4. Pharmaceutical Payments to Japanese Board-Certified Infectious Disease Specialists: A Four-Year Retrospective Analysis of Payments from 92 Pharmaceutical Companies between 2016 and 2019;International Journal of Environmental Research and Public Health;2022-06-16

5. Financial conflicts of interest during meetings of the cardiovascular and renal drugs advisory committee;Journal of Osteopathic Medicine;2022-04-21